Non-inferiority trials: Tyranny or good governance? – Authors' reply Correspondence

  

Authors:	Tannock, I. F.; Buyse, M.; De Backer, M.; Earl, H.; Goldstein, D. A.; Ratain, M. J.; Saltz, L. B.; Sonke, G. S.; Strohbehn, G. W.
Title:	Non-inferiority trials: Tyranny or good governance? – Authors' reply
Keywords:	overall survival; letter; progression free survival; pancreas adenocarcinoma; oxaliplatin; human; pembrolizumab; non-inferiority trial; pharmacodynamic parameters
Journal Title:	Lancet Oncology
Volume:	26
Issue:	1
ISSN:	1470-2045
Publisher:	Elsevier Science, Inc.
Date Published:	2025-01-01
Start Page:	e8
Language:	English
DOI:	10.1016/s1470-2045(24)00717-4
PUBMED:	39756458
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85213506890&doi=10.1016%2fS1470-2045%2824%2900717-4&partnerID=40&md5=d0b18c303944a9aba6be05712e3b0b91
Notes:	Letter -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/222229